New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
08:04 EDTARNAArena Pharmaceuticals and Eisai announce results of Lorcaserin Phase 2 trial
Arena Pharmaceuticals and Eisai announced that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin was recently published in the official peer reviewed journal of The Obesity Society. The objective of these analyses was to identify whether there is an early treatment milestone that can predict greater than or equal to 5% weight loss at one year in patients treated with lorcaserin. Belviq is a serotonin 2C receptor agonist approved in the U.S. as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese or overweight adults with at least one weight-related medical condition, such as high blood pressure, high cholesterol, or type 2 diabetes.
News For ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 11, 2015
19:15 EDTARNAOn The Fly: After Hours Movers
Subscribe for More Information
16:41 EDTARNAArena Pharmaceuticals reports Q1 EPS (10c), consensus (14c)
Subscribe for More Information
16:22 EDTARNAArena Pharmaceuticals enters collaboration with Roivant Sciences
Arena Pharmaceuticals announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Roivant exclusive worldwide rights to develop and commercialize nelotanserin. Nelotanserin has been studied to date in multiple clinical trials involving over 900 subjects. Roivant intends to initiate additional Phase 2 clinical trials for the treatment of behavioral and neuropsychiatric disturbances, including psychoses, in patients with dementia and other neurological diseases. In addition, Roivant may pursue the development of nelotanserin for other neuropsychiatric disorders. Roivant will be responsible for funding the development and commercialization of nelotanserin. Under the agreement, Arena will manufacture clinical supply and commercial product to sell to Roivant. Arena will receive a $4.0M upfront payment and is eligible to receive $41.5M in regulatory and development milestone payments. Arena is also eligible to receive 15% of net sales of nelotanserin in exchange for the manufacture and supply of finished commercial drug product, and up to a total of $60.0M in one-time purchase price adjustment payments tied to certain commercial sales milestones.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use